Since the industrial revolution, there has been a collective Western consensus that technology would continue to propel our world forward, further strengthening our personal and professional lives.

The first cancer cell therapies were personalized treatments made by isolating and engineering a patient’s own T cells in the lab—a complex, cumbersome, and expensive process. A slew of companies are ...

A drug that Bristol Myers Squibb is developing for use across a wide range of autoimmune diseases has failed a mid-stage clinical trial in ulcerative colitis, dimming its prospects in that indication.

Bristol Myers Squibb ponied up $13 billion for MyoKardia last fall, just months after it showed its targeted drug could prevent thickened heart muscle from blocking blood flow in patients with an ...

Bristol Myers Squibb Co. (BMS) and Eisai Co. Ltd. inked a potential $3.1 billion agreement to co-develop and co-commercialize the antibody-drug conjugate (ADC) MORAb-202 for advanced solid tumors.

No one likes to miss the big party. But shareholders of Bristol Myers Squibb (BMY 0.53%) probably feel like they did in 2020. Shares of the drugmaker declined slightly last year while the overall ...

Suppliers of uninterruptible power supply (UPS), battery management systems (BMS), cooling and storage solutions are expected to see their shipments grow along with cloud computing datacenter ...

Many pursuits have been put on hold during the coronavirus pandemic. But biopharmaceutical innovation isn’t one of them. In 2020, the FDA approved 53 new drugs, the second-most in a single year, after ...

Building on a deal first struck in 2019, artificial intelligence (AI) specialist Exscientia Ltd. has agreed to take responsibility for a multitarget drug discovery collaboration with Bristol Myers ...